Soymorphin-Soymorphin-5 (YPFVV), a -opioid agonist peptide derived from the soybean -glycin -subunit, inhibits hyperglycemia in KKAy mice without increasing plasma insulin levels while decreasing plasma and hepatic triglyceride (TG) levels and liver weight, and promotes plasma adiponectin concentration and adiponectin receptor subtype AdipoR2 mRNA expression in the liver, PPAR in the liver after oral administration of soymorphin-5 The mRNA expression of and its target genes was also increased, effectively improving glucose and lipid metabolism in KKAy mice, a type 2 diabetes model animal (75)
Some of the potential side effects include: Inflammation, Erythema, Ecchymoses, and Pruritus at the injection sites
Glutathione reagent and method-patent
Graves disease
For example, in 2008, researchers in China undertook a three-month trial to assess the hypoglycemic effect of berberine versus metformin, a common prescription used to control the blood sugar levels in people with type 2 diabetes
